(HOLX) Hologic - Overview
Stock: Diagnostics, Imaging, Surgical, Skeletal
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 2.87% |
| Relative Tail Risk | -6.54% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.48 |
| Alpha | -4.98 |
| Character TTM | |
|---|---|
| Beta | 0.315 |
| Beta Downside | 0.285 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.85% |
| CAGR/Max DD | -0.07 |
Description: HOLX Hologic January 02, 2026
Hologic Inc. (NASDAQ: HOLX) develops, manufactures, and distributes diagnostics, medical imaging, and surgical solutions focused on women’s health, operating through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
The Diagnostics line includes Aptima molecular assays for infectious diseases (e.g., Hepatitis B/C, HIV, CMV), bacterial vaginosis and candida, as well as SARS-CoV-2 tests; the Breast Health portfolio offers 3-D digital mammography, image-analysis software, and minimally invasive biopsy guidance; GYN Surgical products feature the MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation, and the CoolSeal bipolar vessel sealing devices; Skeletal Health is anchored by the Horizon DXA dual-energy X-ray absorptiometry system.
In FY 2024 Hologic reported $7.9 billion in revenue, with the Diagnostics segment contributing roughly 45 % and posting a 9 % YoY growth rate driven by increased demand for molecular testing post-pandemic. The Breast Health segment remains the most profitable, delivering a 22 % operating margin, while the GYN Surgical line is expanding as minimally invasive procedures gain market share. Key macro drivers include an aging female population, rising prevalence of breast and gynecologic cancers, and favorable reimbursement trends for high-value diagnostic and image-guided procedures.
For a deeper, data-driven assessment of HOLX’s valuation and risk profile, you may find the analyst tools on ValueRay useful.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 543.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -1.89 > 1.0 |
| NWC/Revenue: 70.09% < 20% (prev 61.68%; Δ 8.41% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.10b > Net Income 543.9m |
| Net Debt (352.3m) to EBITDA (1.01b): 0.35 < 3 |
| Current Ratio: 4.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (225.9m) vs 12m ago -2.68% < -2% |
| Gross Margin: 52.82% > 18% (prev 0.56%; Δ 5226 % > 0.5%) |
| Asset Turnover: 46.08% > 50% (prev 46.27%; Δ -0.19% > 0%) |
| Interest Coverage Ratio: 8.00 > 6 (EBITDA TTM 1.01b / Interest Expense TTM 95.2m) |
Altman Z'' 4.85
| A: 0.32 (Total Current Assets 3.84b - Total Current Liabilities 951.3m) / Total Assets 9.18b |
| B: 0.39 (Retained Earnings 3.59b / Total Assets 9.18b) |
| C: 0.09 (EBIT TTM 761.8m / Avg Total Assets 8.95b) |
| D: 0.89 (Book Value of Equity 3.50b / Total Liabilities 3.94b) |
| Altman-Z'' Score: 4.85 = AA |
Beneish M -3.12
| DSRI: 0.91 (Receivables 584.2m/631.4m, Revenue 4.13b/4.04b) |
| GMI: 1.06 (GM 52.82% / 55.98%) |
| AQI: 0.97 (AQ_t 0.52 / AQ_t-1 0.54) |
| SGI: 1.02 (Revenue 4.13b / 4.04b) |
| TATA: -0.06 (NI 543.9m - CFO 1.10b) / TA 9.18b) |
| Beneish M-Score: -3.12 (Cap -4..+1) = AA |
What is the price of HOLX shares?
Over the past week, the price has changed by -0.16%, over one month by -0.13%, over three months by +0.89% and over the past year by +14.30%.
Is HOLX a buy, sell or hold?
- StrongBuy: 3
- Buy: 3
- Hold: 14
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the HOLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 76.9 | 2.8% |
| Analysts Target Price | 76.9 | 2.8% |
| ValueRay Target Price | 76.6 | 2.4% |
HOLX Fundamental Data Overview February 03, 2026
P/E Forward = 16.3934
P/S = 4.0537
P/B = 3.1892
P/EG = 1.5076
Revenue TTM = 4.13b USD
EBIT TTM = 761.8m USD
EBITDA TTM = 1.01b USD
Long Term Debt = 2.50b USD (from longTermDebt, last quarter)
Short Term Debt = 9.30m USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 352.3m USD (from netDebt column, last quarter)
Enterprise Value = 16.88b USD (16.73b + Debt 2.52b - CCE 2.36b)
Interest Coverage Ratio = 8.00 (Ebit TTM 761.8m / Interest Expense TTM 95.2m)
EV/FCF = 16.89x (Enterprise Value 16.88b / FCF TTM 999.6m)
FCF Yield = 5.92% (FCF TTM 999.6m / Enterprise Value 16.88b)
FCF Margin = 24.22% (FCF TTM 999.6m / Revenue TTM 4.13b)
Net Margin = 13.18% (Net Income TTM 543.9m / Revenue TTM 4.13b)
Gross Margin = 52.82% ((Revenue TTM 4.13b - Cost of Revenue TTM 1.95b) / Revenue TTM)
Gross Margin QoQ = 55.96% (prev 60.90%)
Tobins Q-Ratio = 1.84 (Enterprise Value 16.88b / Total Assets 9.18b)
Interest Expense / Debt = 1.10% (Interest Expense 27.6m / Debt 2.52b)
Taxrate = 22.03% (50.6m / 229.7m)
NOPAT = 594.0m (EBIT 761.8m * (1 - 22.03%))
Current Ratio = 4.04 (Total Current Assets 3.84b / Total Current Liabilities 951.3m)
Debt / Equity = 0.48 (Debt 2.52b / totalStockholderEquity, last quarter 5.25b)
Debt / EBITDA = 0.35 (Net Debt 352.3m / EBITDA 1.01b)
Debt / FCF = 0.35 (Net Debt 352.3m / FCF TTM 999.6m)
Total Stockholder Equity = 4.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.07% (Net Income 543.9m / Total Assets 9.18b)
RoE = 11.01% (Net Income TTM 543.9m / Total Stockholder Equity 4.94b)
RoCE = 10.24% (EBIT 761.8m / Capital Employed (Equity 4.94b + L.T.Debt 2.50b))
RoIC = 7.97% (NOPAT 594.0m / Invested Capital 7.45b)
WACC = 6.26% (E(16.73b)/V(19.25b) * Re(7.08%) + D(2.52b)/V(19.25b) * Rd(1.10%) * (1-Tc(0.22)))
Discount Rate = 7.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.03%
[DCF Debug] Terminal Value 83.95% ; FCFF base≈1.05b ; Y1≈968.1m ; Y5≈878.3m
Fair Price DCF = 104.2 (EV 23.61b - Net Debt 352.3m = Equity 23.26b / Shares 223.2m; r=6.26% [WACC]; 5y FCF grow -9.37% → 2.90% )
EPS Correlation: -16.25 | EPS CAGR: -16.77% | SUE: -2.96 | # QB: 0
Revenue Correlation: -27.58 | Revenue CAGR: -8.06% | SUE: -3.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.08 | Chg30d=-0.020 | Revisions Net=+2 | Analysts=9
EPS current Year (2026-09-30): EPS=4.48 | Chg30d=-0.079 | Revisions Net=-3 | Growth EPS=+5.2% | Growth Revenue=+3.9%
EPS next Year (2027-09-30): EPS=3.85 | Chg30d=-0.157 | Revisions Net=-1 | Growth EPS=+11.7% | Growth Revenue=+5.3%